IQ EQ FUND MANAGEMENT IRELAND Ltd Sells 1,219 Shares of Kenvue Inc. (NYSE:KVUE)

IQ EQ FUND MANAGEMENT IRELAND Ltd cut its stake in shares of Kenvue Inc. (NYSE:KVUE) by 1.3% in the 4th quarter, Holdings Channel reports. The institutional investor owned 92,242 shares of the company’s stock after selling 1,219 shares during the quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd’s holdings in Kenvue were worth $1,969,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. State Street Corp increased its holdings in Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock worth $2,942,458,000 after purchasing an additional 18,283,473 shares in the last quarter. Boston Partners increased its stake in shares of Kenvue by 36.9% in the fourth quarter. Boston Partners now owns 23,595,963 shares of the company’s stock valued at $503,145,000 after buying an additional 6,366,097 shares during the period. Holocene Advisors LP raised its holdings in Kenvue by 75.5% in the 3rd quarter. Holocene Advisors LP now owns 13,886,454 shares of the company’s stock valued at $321,194,000 after buying an additional 5,975,392 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Kenvue during the 4th quarter worth approximately $98,926,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Kenvue by 30.2% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 9,992,933 shares of the company’s stock worth $231,137,000 after acquiring an additional 2,316,443 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Trading Up 1.3 %

NYSE:KVUE opened at $23.40 on Thursday. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $44.72 billion, a price-to-earnings ratio of 44.15, a PEG ratio of 2.62 and a beta of 1.25. The firm has a fifty day simple moving average of $22.22 and a two-hundred day simple moving average of $22.45.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.50%. The ex-dividend date was Wednesday, February 12th. Kenvue’s payout ratio is 154.72%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price target for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Barclays cut their target price on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday, January 17th. Piper Sandler increased their price target on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. UBS Group cut their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Kenvue presently has a consensus rating of “Hold” and an average price target of $23.85.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.